(Q36971042)

17 August 2017

1 reference

title

HCV-related autoimmune and neoplastic disorders: the HCV syndrome (English)

1 reference

17 August 2017

8

Zignego AL

1 reference

17 August 2017

Ferri C

1

1 reference

17 August 2017

Antonelli A

2

1 reference

17 August 2017

Mascia MT

3

1 reference

17 August 2017

Sebastiani M

4

1 reference

17 August 2017

Fallahi P

5

1 reference

17 August 2017

Ferrari D

6

1 reference

17 August 2017

Pileri SA

7

1 reference

17 August 2017

1 September 2007

1 reference

Digestive and Liver Disease

17 August 2017

1 reference

17 August 2017

39 Suppl 1

1 reference

17 August 2017

S13-21

1 reference

Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach

17 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Extrahepatic disease manifestations of HCV infection: some current issues

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

1 reference

7 January 2021

Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Infection of peripheral mononuclear blood cells by hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

The cryoglobulins: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Hepatitis C virus induces toll-like receptor 4 expression, leading to enhanced production of beta interferon and interleukin-6

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Hepatitis C virus drives the unconstrained monoclonal expansion of VH1-69-expressing memory B cells in type II cryoglobulinemia: a model of infection-driven lymphomagenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Thyroid cancer in patients with hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Essential mixed cryoglobulinemia, type II: a manifestation of a low-grade malignant lymphoma? Clinical-morphological study of 12 cases with special reference to immunohistochemical findings in liver frozen sections

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Non HCV-related mixed cryoglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Hepatitis C virus infection mimicking primary Sjögren syndrome. A clinical and immunologic description of 35 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Hepatitis C-associated arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

OPG/RANKL system imbalance in a case of hepatitis C-associated osteosclerosis: the pathogenetic key?

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Prevalence of fibromyalgia, anxiety and depression in chronic hepatitis C virus infection: relationship to RT-PCR status and mode of acquisition

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Polymyositis, lung fibrosis, and cranial neuropathy in a patient with hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Interstitial lung fibrosis and rheumatic disorders in patients with hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Cryoglobulinaemia and rheumatic manifestations in patients with hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Sjögren syndrome associated with hepatitis C virus: a multicenter analysis of 137 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Thyroid abnormalities in patients with chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

High prevalence of antibodies to hepatitis C virus (HCV) in patients with anti-thyroid autoantibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Geographical distribution of subclinical autoimmune thyroid disease in Britain: a study using highly sensitive direct assays for autoantibodies to thyroglobulin and thyroid peroxidase

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Effects of excess iodine administration on thyroid function in euthyroid patients with a previous episode of thyroid dysfunction induced by interferon-alpha treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Thyroid disorders in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Thyroid involvement in patients with overt HCV-related mixed cryoglobulinaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Association of diabetes mellitus and chronic hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Hepatitis C infection and type 2 diabetes in American-Indian women

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Is type II diabetes another extrahepatic manifestation of HCV infection?

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

High prevalence of glucose abnormalities in patients with hepatitis C virus infection: a multivariate analysis considering the liver injury

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

HCV and diabetes mellitus: evidence for a negative association

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Hepatitis C virus infection: evidence for an association with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Erectile dysfunction and hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Hepatitis C virus and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Hepatitis C virus infection in patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

HCV and non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Indolent lymphoma: the pathologist's viewpoint.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Hepatitis C virus-associated tubulointerstitial injury

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Renal manifestations of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Renal manifestations of hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Membranous glomerulonephritis associated with hepatitis C virus infection: case report and literature review.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Porphyrin metabolism in hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Hepatitis C virus-related autoimmunity in patients with porphyria cutanea tarda

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Prevalence of hepatitis C virus infection in porphyria cutanea tarda

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Hepatitis C virus and lichen planus

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Hepatitis C virus infection and cardiomyopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Hepatitis C virus chronic infection as a common cause of mixed cryoglobulinaemia and autoimmune liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2807%2980005-3

7 January 2021

10.1016/S1590-8658(07)80005-3

Identifiers

DOI

1 reference

17 August 2017

1 reference